Articles tagged with Neuroblastoma
Researchers paired CAR T cell immunotherapy with a targeted radiopharmaceutical to improve tumor regression in preclinical models of neuroblastoma. The combination therapy worked through different mechanisms depending on the tumor's sensitivity to radiation.
Researchers develop AI framework using principles of superposition and entanglement to tailor cancer treatment to patients' entire molecular background. The technique predicts health outcomes and suggests genes to target, outperforming standard biomarkers in clinical trials.
Researchers developed an mRNA vaccine that targets neuroblastoma, delaying tumour development by 10-11 days and reducing tumour size by 70% in preclinical models. The vaccine uses peptide nanoparticles to target GPC2, a protein found on the surface of neuroblastoma cells.
Researchers have discovered a way to prevent the collaboration between two important cancer-related proteins, N-MYC and Aurora A. This breakthrough could lead to new medications to combat childhood cancer. The study, published in Nature Communications, provides insights into how these proteins interact with each other.
Researchers created a detailed map of neuroblastoma, a childhood cancer, using cutting-edge technology. They found that high-risk tumors carry a defense mechanism against ferroptosis, a natural cancer-killing process, but it's shielded by the protein GPX4.
Research found that certain NSUN6 gene polymorphisms may reduce the risk of neuroblastoma in children from Jiangsu Province, China. The study also discovered a potential link between these genetic variants and improved overall survival rates.
A major study has shown that tumour stage at diagnosis is strongly linked to childhood cancer survival across six different cancers. Researchers analysed data from 9,883 children in 27 countries and found significant variation in three-year survival rates between regions, particularly in the UK and Ireland.
A study published in EMBO Molecular Medicine has identified a combination of statins and phenothiazines that shows promise in treating aggressive neuroblastoma. The drug combination was found to impede tumour growth and improve survival rates in laboratory trials with mice.
Australian researchers have discovered a drug combination that can bypass the cellular defenses developed by neuroblastoma tumors, making it more effective against relapsed cases. The combination reduces tumor growth and extends survival time compared to standard treatment alone.
A study by researchers at Umeå University found that high levels of HIF2α protein can reduce tumour growth and promote maturation of neuroblastoma cells. The findings challenge previous views on the role of HIF2α in cancer development.
Researchers have developed a novel therapeutic approach that combines difluoromethylornithine with a targeted diet to enhance the effectiveness of treatment in high-risk neuroblastoma patients. The diet blocks the formation of polyamine precursors, amplifying the drug's effects and driving cancer cells to mature.
A study published in the Lancet Child and Adolescent Health journal found that high-risk neuroblastoma survivors experience a high prevalence of hearing loss, growth failure, underweight, and lung disease due to modern therapies. Longer follow-up periods were associated with a higher risk of late effects.
Researchers from St. Jude Children's Research Hospital have made a breakthrough in treating neuroblastoma by combining immunotherapy with the drug indisulam, achieving complete therapeutic responses in laboratory models regardless of cell state.
Cancer cells with abundant circular DNA elements (ecDNA) carrying oncogenes like MYCN are resistant to chemotherapy. Combining standard chemotherapy with a secondary therapy targeting these senescent cells leads to improved outcomes in mouse models of neuroblastoma and medulloblastoma.
Researchers developed a machine learning framework to identify prognostic biomarkers in neuroblastoma, revealing 11 key genes including RFC3 strongly linked to poor survival outcomes and immune evasion. These biomarkers also hint at responsiveness to existing chemotherapy drugs.
Neuroblastoma is often difficult to treat due to its ability to enter a dormant state when the MYCN gene is located outside chromosomes. A new study proposes targeting these dormant tumor cells with a combination of chemotherapy and a second drug, showing promising results in mouse models.
Researchers identified 'uncommitted' cells in neuroblastoma tumors that exhibit weaker cancer development, potentially leading to favorable outcomes for patients. These cells may help identify early diagnostic markers and novel therapeutic targets.
Researchers from the University of Southampton engineered a new type of super-strong antibody that triggers a stronger response from the immune system compared to naturally produced antibodies. The study confirms that making subtle increases in rigidity stimulates immune activity, creating a powerful immune response against disease.
Scientists at St. Jude Children's Research Hospital discovered FOXR2 activation in multiple pediatric CNS tumor types, including high-grade gliomas and pineoblastomas, with significantly different clinical outcomes. The study highlights the importance of combining molecular findings with other diagnostic approaches to improve treatment...
Researchers investigated the neuroregenerative potential of 5-NOT and Epi, discovering they protected SH-SY5Y cells from MPP+ toxicity by regulating key proteins. The findings support 5-NOT as a glycomimetic drug candidate for Parkinson's disease treatment.
Researchers developed a predictive model for neuroblastoma bone marrow metastasis using AI, identifying key genomic and single-cell transcriptomic alterations. The study also uncovered the role of oxidative phosphorylation, transketolase, and immune checkpoint genes in BBM progression.
Scientists at St. Jude Children's Research Hospital have uncovered the mechanism by which retinoic acid selectively kills metastatic neuroblastoma cells, using a novel pathway to trigger cancer cell death. The findings have implications for future combination therapy approaches.
Targeting MYCN and MDM2 oncogenes offers a promising strategy for cancer therapy, particularly in neuroblastoma. The review highlights the potential benefits of dual-targeted inhibition, which can restrain both MYCN-mediated tumorigenesis and MDM2-regulated survival.
Researchers aim to understand MYCN-driven immune escape in neuroblastoma, a common childhood cancer, and develop targeted therapies to enhance immunotherapy responses. The study will investigate the potential of inhibiting tumor-secreted CKLF1 to alleviate immunosuppression and improve treatment outcomes.
Researchers from the University of Gothenburg have discovered that blocking the METTL3 protein can increase sensitivity to chemotherapy in neuroblastoma, a type of cancer primarily affecting young children. This study suggests that METTL3 inhibitors could be used as a new treatment strategy for high-risk neuroblastoma, especially for c...
Researchers have found that natural killer cells instinctively recognize and attack the XPO1 protein, which drives cancer growth. By targeting this protein, scientists may be able to activate more killer cells to destroy cancer cells. The study suggests that this approach could lead to personalized cancer treatment with less side effects.
A novel PET/CT technique has been developed to detect neuroblastoma in children with high sensitivity and short scan time, eliminating the need for sedation or anesthesia. The new technique uses a novel tracer and next-generation scanner, resulting in improved diagnostic accuracy and reduced radiation exposure.
Researchers at the University of Chicago show that a drug molecule targeting RNA modifications associated with neuroblastoma suppresses tumor growth in mice. High levels of METTL3 expression were linked to significantly lower survival rates in patients, suggesting it drives tumor growth.
Researchers have identified three new subgroups of neuroblastoma based on genetic traits, expected outcomes, and distinguishing features. These subgroups offer clues as to which treatments may be most effective, potentially improving prognosis and quality of life for children with cancer.
Researchers at IBEC have created in vitro models of neuroblastoma vasculature, replicating the tumor's characteristic blood vessel formation and identifying GB3 as a potential therapeutic target. The study uses stiffness-based models and microfluidic chips to explore treatments for this pediatric cancer.
A study investigated the association between miR-492 rs2289030 G>C polymorphism and neuroblastoma susceptibility in Chinese children. The results showed no significant impact of the polymorphism on neuroblastoma risk, suggesting a need for further validation with larger samples.
Researchers at St. Jude Children's Research Hospital discovered a potential therapeutic target for high-risk neuroblastoma by studying the cellular personality switch driven by the MYCN protein. Inhibiting the protein KDM4 showed promising anticancer activity, blocking MYCN expression and repressing key oncogenes in disease models.
Researchers at UCSF have identified AF1q as a universal biomarker for neuroblastoma, a highly aggressive and fatal form of childhood cancer. High-risk cases have a five-year survival rate of just 50%. The study found that silencing AF1q in neuroblastoma cells induces cell death and weakens tumor progression.
Liquid biopsies have the potential to monitor therapy success and predict tumor recurrence in high-risk neuroblastoma patients. The MONALISA project aims to establish liquid biopsies as a standard procedure for monitoring relapsed neuroblastoma, offering hope for improved personalized medicine.
Researchers have identified UCHL1, a protein found in highly aggressive neuroendocrine carcinomas and neuroblastoma, as a potential molecular biomarker for diagnosing these cancers and predicting responses to therapy. Targeting UCHL1 with inhibitors has been shown to delay the growth and spread of these tumors in pre-clinical models.
A new trial found that combining anti-angiogenic drugs with chemotherapy led to more young people seeing their tumors shrink, from 18% in the control group to 26%. Patients who received Bevacizumab additionally had better one year progression-free survival rates.
Researchers at Nemours Children's Health discovered that injecting neuroblastoma tumors with Zika virus shrank or eliminated those tumors in mice, suggesting a potential new therapy. The study showed promising results, with complete tumor elimination and no recurrence after four weeks of follow-up.
Scientists have mapped neuroblastoma tumors at the cell level and discovered a brake on the immune system that can be blocked with existing immunotherapy. A new combination treatment targeting TIGIT and PD-L1 is being developed, showing promising results in lab experiments.
José Pedro Friedmann Angeli, a pioneer in ferroptosis research, has received the ERC Consolidator Grant to explore key metabolic pathways. His project aims to decipher and exploit ferroptosis regulatory mechanisms in cancer.
Researchers at the University of Cambridge have made a groundbreaking discovery that could lead to more effective treatments for neuroblastoma, a devastating form of childhood cancer. The new approach uses a combination of two drugs to encourage cancer cells to become normal non-dividing cells, potentially reducing side effects.
Researchers discovered that inhibiting IGF2BP1 can extinguish its cancer-causing effects, leading to the formation of neuroblastomas. The study provides a promising new potential therapeutic approach for treating this childhood cancer.
A new approach to immunotherapy has shown long-term survival rates exceeding 50% in children with high-risk neuroblastoma. Stem cell transplantation from a parent provides a renewed immune system that responds better to immunotherapies, improving outcomes.
Researchers found that cancer cells prevent surrounding cells from fighting tumors, but medication can reverse this process. Metastatic tumor cells retain cellular plasticity and change gene expression based on the neuroblastoma genetic subtype.
Researchers at Baylor College of Medicine report well-tolerated CAR-NKT cell therapy with strong antitumor activity in patients with stage 4 relapsed neuroblastoma. The treatment, which targets a molecule found on the surface of neuroblastoma cells, showed encouraging results in three patients with complete and partial responses.
A new study has provided insight into the mysterious evolution of DNA rings in tumors, revealing that nearly one-third of all tumors have these genetic structures. The researchers used a technology to trace the path of DNA ring development in neuroblastoma cells, finding that large rings contain cancer genes spurring cell growth.
Researchers have shown lorlatinib to be safe and effective in treating high-risk neuroblastoma with ALK gene mutations. The targeted therapy has led to a major amendment in a phase 3 clinical trial, offering new hope for patients with this often lethal cancer.
Researchers have developed a new technique that combines real-time images with short-wave infrared light to differentiate between cancerous tumours and healthy tissue. This innovation has the potential to improve treatment outcomes for neuroblastoma patients by allowing surgeons to remove cancerous cells more precisely.
Tumour cells exhibit an innate randomness in their ability to respond to chemotherapy, which can lead to resistance. Researchers identified a marker for resistance and propose combining chemotherapy with drugs targeting this 'noise' to improve treatment outcomes.
Hollings researchers create small molecule that targets CD38 enzyme activity, stimulating proliferation of natural killer cells and enhancing anti-cancer activity. The compound has potential as an adjuvant therapy to boost effects of existing treatments and reduce resistance to monoclonal antibodies.
Researchers at the Princess Máxima Center found that concentrating surgery for children with neuroblastoma resulted in shorter operation times and reduced blood loss. The study also showed a decrease in side effects, although further research is needed to confirm improved survival rates.
Researchers analyzed COX-2 levels and segmental chromosome aberrations in pediatric neuroblastoma tumor samples. Positive correlations between pre-CT Ch 7q gain and COX-2 expression were found, as well as negative correlations between Ch 7q gain and Ch 11q deletion.
Medical University of South Carolina researchers develop a novel LSD1 inhibitor that shows early promise at fighting neuroblastoma when paired with bortezomib. The combination boosts anti-tumor response and is a viable strategy for targeting high-risk MYCN-amplified neuroblastoma.
Neuroblastoma tumour cells adapt to mimic embryonic cells, making them resistant to chemotherapy. This understanding can lead to targeted treatments that better reach the entire tumour and avoid resistance development.
A team of scientists has discovered a novel non-invasive method to predict and reduce the relapse of childhood cancers, particularly neuroblastoma. The new approach analyzes genes in blood samples to determine the likelihood of cancer spread, allowing for early interventions to prevent relapse.
Researchers at Karolinska Institutet have developed a potential curative treatment for neuroblastoma, using DHODH blockers in combination with chemotherapy to cure mice with the disease. The treatment has shown promising results and could improve survival rates for children with neuroblastoma.
Neuroblastoma cells with extra copies of the MYCN gene rely on fatty acids for survival and growth. Inhibiting fatty acid uptake selectively blocks tumor growth in these cells.
A recent study published in Cancer Research identified a unique vulnerability in certain high-risk cancers that can be exploited for targeted therapy. Researchers found that cancer cells with alternative lengthening of telomeres (ALT) have a common weakness, leading to resistance to DNA-damaging agents and chemotherapy.
Researchers at VCU Massey Cancer Center have discovered a new target for treating high-risk neuroblastoma, a deadly pediatric cancer. A novel compound called SHP099 has shown promising results in shrinking tumors and killing cancer cells.
Researchers found that a bridge therapy approach prior to consolidation therapy can improve event-free survival in patients with stable metastatic cancer after induction therapy. Patients who received this treatment had significantly better outcomes compared to those who underwent direct consolidation or post-induction therapy alone.
Children from marginalized groups and those with public insurance had poorer five-year survival rates, even when receiving standardized treatment. The study highlights the need for healthcare delivery and supportive care interventions to mitigate racial and ethnic disparities in childhood cancer.